References
- Allen, M. (2017). The SAGE encyclopedia of communication research methods. Sage Publications.
- Bach, P., & Hartung, D. (2019). Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders. Addiction Science & Clinical Practice, 14(1), 30https://doi.org/https://doi.org/10.1186/s13722-019-0158-0
- Bachyrycz, A., Shrestha, S., Bleske, B. E., Tinker, D., & Bakhireva, L. N. (2017). Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery. Substance Abuse, 38(1), 55–60. https://doi.org/https://doi.org/10.1080/08897077.2016.1184739
- Bailey, A. M., & Wermeling, D. P. (2014). Naloxone for opioid overdose prevention: Pharmacists’ role in community-based practice settings. The Annals of Pharmacotherapy, 48(5), 601–606. https://doi.org/https://doi.org/10.1177/1060028014523730
- Borgatti, S. (2005). Introduction to grounded theory. Retrieved May 15, 2010. http://www.analytictech.com/mb870/introtogt.htm
- Bratberg, J. P., Smothers, Z. P. W., Collins, K., Erstad, B., Ruiz Veve, J., & Muzyk, A. J. (2020). Pharmacists and the opioid crisis: A narrative review of pharmacists’ practice roles. Jaccp: Journal of the American College of Clinical Pharmacy, 3(2), 478–484. https://doi.org/https://doi.org/10.1002/jac5.1171
- CDC. (2018a). Annual surveillance report of drug-related risks and outcomes — United States. Surveillance Special Report 2. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services.
- CDC. (2018b, March 5). U.S. opioid prescribing rate maps. https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html
- Chisholm-Burns, M. A., Spivey, C. A., Sherwin, E., Wheeler, J., & Hohmeier, K. (2019). The opioid crisis: Origins, trends, policies, and the roles of pharmacists. American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists, 76(7), 424–435. https://doi.org/https://doi.org/10.1093/ajhp/zxy089
- Cicero, T. J., Ellis, M. S., Surratt, H. L., & Kurtz, S. P. (2014). The changing face of heroin use in the United States: A retrospective analysis of the past 50 years. JAMA Psychiatry, 71(7), 821–826. https://doi.org/https://doi.org/10.1001/jamapsychiatry.2014.366
- Cochran, G., Bruneau, J., Cox, N., & Gordon, A. J. (2020). Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic. Substance Abuse, 41(3), 269–274. https://doi.org/https://doi.org/10.1080/08897077.2020.1787300
- Cochran, G., Field, C., Karp, J., Seybert, A. L., Chen, Q., Ringwald, W., Hruschak, V., Chickering, S., Kincman, J., Jaber, A., & Tarter, R. (2018). A community pharmacy intervention for opioid medication misuse: A pilot randomized clinical trial. Journal of the American Pharmacists Association : JAPhA, 58(4), 395–403. https://doi.org/https://doi.org/10.1016/j.japh.2018.03.005
- Cochran, G., Field, C., Lawson, K., & Erickson, C. (2013). Pharmacists’ knowledge, attitudes and beliefs regarding screening and brief intervention for prescription opioid abuse: A survey of Utah and Texas pharmacists. Journal of Pharmaceutical Health Services Research, 4(2), 71–79. https://doi.org/https://doi.org/10.1111/jphs.12013
- Cochran, G., Hruschak, V., DeFosse, B., & Hohmeier, K. C. (2016). Prescription opioid abuse: Pharmacists’ perspective and response. Integrated Pharmacy Research & Practice, 5, 65–73. https://doi.org/https://doi.org/10.2147/IPRP.S99539
- Cooper, H. L., Cloud, D. H., Freeman, P. R., Fadanelli, M., Green, T., Van Meter, C., Beane, S., Ibragimov, U., & Young, A. M. (2020). Buprenorphine dispensing in an epicenter of the US opioid epidemic: A case study of the rural risk environment in Appalachian Kentucky. The International Journal on Drug Policy, 85, 102701. https://doi.org/https://doi.org/10.1016/j.drugpo.2020.102701
- Cox, N., Tak, C. R., Cochella, S. E., Leishman, E., & Gunning, K. (2018). Impact of pharmacist previsit input to providers on chronic opioid prescribing safety. The Journal of the American Board of Family, 31(1), 105–112. https://doi.org/https://doi.org/10.3122/jabfm.2018.01.170210
- Davenport, E. S., Arnett, S. J., Nichols, M. A., & Miller, M. L. (2020). Indiana community pharmacist preceptors’ knowledge and perceptions of medication-assisted treatment. Journal of the American Pharmacists Association, 60(3), S20–S28. https://doi.org/https://doi.org/10.1016/j.japh.2020.01.001
- Elo, S., & Kyngäs, H. (2008). The qualitative content analysis process. Journal of Advanced Nursing, 62(1), 107–115. https://doi.org/https://doi.org/10.1111/j.1365-2648.2007.04569.x
- Fischer, B., Jones, W., Tyndall, M., & Kurdyak, P. (2020). Correlations between opioid mortality increases related to illicit/synthetic opioids and reductions of medical opioid dispensing - exploratory analyses from Canada. BMC Public Health, 20(1), 143–147. https://doi.org/https://doi.org/10.1186/s12889-020-8205-z
- Fleming, M. L., Bapat, S. S., & Varisco, T. J. (2019). Using the theory of planned behavior to investigate community pharmacists’ beliefs regarding engaging patients about prescription drug misuse. Research in Social & Administrative Pharmacy : RSAP, 15(8), 992–999. https://doi.org/https://doi.org/10.1016/j.sapharm.2018.10.027
- Gavaza, P., Fleming, M., & Barner, J. C. (2014). Examination of psychosocial predictors of Virginia pharmacists’ intention to utilize a prescription drug monitoring program using the theory of planned behavior. Research in Social and Administrative Pharmacy, 10(2), 448–458. https://doi.org/https://doi.org/10.1016/j.sapharm.2013.06.011
- Giannitrapani, K. F., Glassman, P. A., Vang, D., McKelvey, J. C., Thomas Day, R., Dobscha, S. K., & Lorenz, K. A. (2018). Expanding the role of clinical pharmacists on interdisciplinary primary care teams for chronic pain and opioid management. BMC Family Practice, 19(1), 107https://doi.org/https://doi.org/10.1186/s12875-018-0783-9
- Hagemeier, N. E., Tudiver, F., Brewster, S., Hagy, E. J., Ratliff, B., Hagaman, A., & Pack, R. P. (2018). Interprofessional prescription opioid abuse communication among prescribers and pharmacists: A qualitative analysis. Substance Abuse, 39(1), 89–94. https://doi.org/https://doi.org/10.1080/08897077.2017.1365803
- Hartung, D. M., Hall, J., Haverly, S. N., Cameron, D., Alley, L., Hildebran, C., O’Kane, N., & Cohen, D. (2018). Pharmacists’ role in opioid safety: A focus group investigation. Pain Medicine (Malden, Mass.), 19(9), 1799–1806. https://doi.org/https://doi.org/10.1093/pm/pnx139
- Hsieh, H.-F., & Shannon, S. E. (2005). Three approaches to qualitative content analysis. Qualitative Health Research, 15(9), 1277–1288. [Database] https://doi.org/https://doi.org/10.1177/1049732305276687
- Jensen, B., Chen, J., Furnish, T., & Wallace, M. (2015). Medical marijuana and chronic pain: A review of basic science and clinical evidence. Current Pain and Headache Reports, 19(10), 50. https://doi.org/https://doi.org/10.1007/s11916-015-0524-x
- Lofton, J. C., & Owen, J. A. (2014). Pharmacists’ role in addressing opioid abuse, addiction, and diversion. Journal of the American Pharmacists Association : JAPhA, 54(1), e5–15. https://doi.org/https://doi.org/10.1331/JAPhA.2014.13101
- Moride, Y., Lemieux-Uresandi, D., Castillon, G., de Moura, C. S., Pilote, L., Faure, M., & Bernartsky, S. (2019). A systematic review of interventions and programs targeting appropriate prescribing of opioids. Pain Physician, 22(3), 229–240.
- Muzyk, A., Smothers, Z. P., Collins, K., MacEachern, M., & Wu, L.-T. (2019). Pharmacists’ attitudes toward dispensing naloxone and medications for opioid use disorder: A scoping review of the literature. Substance Abuse, 40(4), 476–483. https://doi.org/https://doi.org/10.1080/08897077.2019.1616349
- NIDA. ( 2019, January 22). Opioid overdose crisis. National Institute on Drug Abuse website. https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis.
- Rao, D., Giannetti, V., Kamal, K. M., Covvey, J. R., & Tomko, J. R. (2020). The relationship between knowledge, attitudes, and practices of community pharmacists regarding persons with substance use disorders. Substance Abuse, 1–8. https://doi.org/https://doi.org/10.1080/08897077.2020.1809605
- Rothstein, M. A. (2017). The opioid crisis and the need for compassion in pain management. American Public Health Association.
- Salwan, A., Hagemeier, N. E., Tudiver, F., Dowling-McClay, K., Foster, K. N., Arnold, J., Alamian, A., & Pack, R. P. (2020). Community pharmacist engagement in opioid use disorder prevention and treatment behaviors: A descriptive analysis. Journal of the American Pharmacists Association : JAPhA, 60(6), e173–e178. https://doi.org/https://doi.org/10.1016/j.japh.2020.06.008
- SAMHSA. (2019). Medications for opioid use disorder. Treatment Improvement Protocol (TIP) Series 63, full document. HHS Publication No.(SMA) 18-5063FULLDOC. 2018.
- Skoy, E., Eukel, H., Werremeyer, A., Strand, M., Frenzel, O., & Steig, J. (2020). Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose. Journal of the American Pharmacists Association: JAPhA, 60(1), 117–121. https://doi.org/https://doi.org/10.1016/j.japh.2019.09.003
- Walley, A. Y., Xuan, Z., Hackman, H. H., Quinn, E., Doe-Simkins, M., Sorensen-Alawad, A., Ruiz, S., & Ozonoff, A. (2013). Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: Interrupted time series analysis. BMJ (Clinical Research ed.), 346, f174. https://doi.org/https://doi.org/10.1136/bmj.f174
- Werremeyer, A., Mosher, S., Eukel, H., Skoy, E., Steig, J., Frenzel, O., & Strand, M. A. (2021). Pharmacists’ stigma toward patients engaged in opioid misuse: When "social distance" does not mean disease prevention. Substance Abuse, 1–8. https://doi.org/https://doi.org/10.1080/08897077.2021.1900988